Mercer International Inc. Reports Third Quarter 2024 Results and Announces Quarterly Cash Dividend of $0.075
Selected Highlights Third quarter Operating EBITDA* increased by 35% to $50.5 million (net loss of $17.6 million) from $37.5 million […]
Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously […]
USCB Financial Holdings, Inc. Reports Record Fully Diluted EPS of $0.35 for Q3 2024; ROAA of 1.11% and ROAE of 13.38%
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) — USCB Financial Holdings, Inc. (the “Company”) (NASDAQ: USCB), the holding company for U.S. […]
Commercial Vehicle Group Announces New Executive Appointments to Accelerate Performance
NEW ALBANY, Ohio, Oct. 31, 2024 (GLOBE NEWSWIRE) — Commercial Vehicle Group (the “Company” or “CVG”) (NASDAQ: CVGI), a diversified […]
Trident Rings the Nasdaq Opening Bell Following Successful U.S. Listing
SINGAPORE, Nov. 01, 2024 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd. (Nasdaq: TDTH) (“Trident” or the “Company”), a leading […]
Timberland Bancorp Reports Fourth Fiscal Quarter Net Income of $6.36 Million
Quarterly EPS of $0.79 and Fiscal Year EPS of $3.01 Quarterly Return on Average Assets of 1.32% Quarterly Return on […]
Progress Completes Acquisition of ShareFile
ShareFile’s AI-powered, document-centric collaboration platform expands Progress’ industry-leading product portfolio and marks a major milestone in the company’s Total Growth Strategy […]
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
– Patient characteristics are consistent with other DLB studies – PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, […]
Enstar Completes Loss Portfolio Transfer With QBE
HAMILTON, Bermuda, Oct. 31, 2024 (GLOBE NEWSWIRE) — Enstar Group Limited (NASDAQ: ESGR) announced today that one of its wholly-owned […]
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 […]
